| 0.6938 0.015 (2.18%) | 04-26 13:56 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.08  |
1-year : | 1.29 |
| Resists | First : | 0.92 |
Second : | 1.11 |
| Pivot price | 0.79 |
|||
| Supports | First : | 0.63 | Second : | 0.52 |
| MAs | MA(5) : | 0.7 |
MA(20) : | 0.82 |
| MA(100) : | 1.22 |
MA(250) : | 1.34 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 9.7  |
D(3) : | 7.8 |
| RSI | RSI(14): 19.3 |
|||
| 52-week | High : | 1.85 | Low : | 0.63 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LUCD ] has closed above bottom band by 12.7%. Bollinger Bands are 38.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.68 - 0.69 | 0.69 - 0.69 |
| Low: | 0.62 - 0.63 | 0.63 - 0.63 |
| Close: | 0.66 - 0.67 | 0.67 - 0.68 |
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Mon, 08 Apr 2024
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference - PR Newswire
Tue, 26 Mar 2024
Lucid Diagnostics Inc. (LUCD) Q4 2023 Earnings Call Transcript - Seeking Alpha
Mon, 25 Mar 2024
Lucid Diagnostics reports 33% quarterly revenue jump By Investing.com - Investing.com
Mon, 25 Mar 2024
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results - PR Newswire
Thu, 21 Mar 2024
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard ... - PR Newswire
Tue, 12 Mar 2024
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024 - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 1.507e+007 (%) |
| Held by Institutions | 70.3 (%) |
| Shares Short | 203 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.598e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 101.2 % |
| Return on Equity (ttm) | -101.4 % |
| Qtrly Rev. Growth | 2.43e+006 % |
| Gross Profit (p.s.) | 511.48 |
| Sales Per Share | -313.57 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -33 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | -2.19 |
| Dividend | 0 |
| Forward Dividend | 440960 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|